HNSCC
Clinical trials for HNSCC explained in plain language.
Never miss a new study
Get alerted when new HNSCC trials appear
Sign up with your email to follow new studies for HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug combo aims at genetic weaknesses in head and neck cancer
Disease control CompletedThis early-stage trial tested a combination of two oral drugs, tipifarnib and alpelisib, in 45 adults with recurrent or metastatic head and neck squamous cell carcinoma that has specific genetic changes (HRAS overexpression or PIK3CA mutations). The goal was to find a safe dose a…
Matched conditions: HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Matched conditions: HNSCC
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Immunotherapy duo shows promise against tough cancers
Disease control CompletedThis study tested a combination of two immunotherapy drugs (eftilagimod alpha and pembrolizumab) in 187 people with advanced lung cancer or head/neck cancer that had not been treated or had stopped responding to prior therapy. The goal was to see if the combination could shrink t…
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy combo shows promise in head and neck cancer trial
Disease control CompletedThis phase 2 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy and radiation after surgery could help prevent cancer from returning in people with advanced head and neck cancer. The study enrolled 211 patients who had their tumor…
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: University of Leipzig • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug combo shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis study tested a combination of two drugs, pembrolizumab and cetuximab, in 78 people with advanced head and neck cancer that had returned or spread. The goal was to see if the combination could shrink tumors or slow the disease. Participants were grouped based on whether they …
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy shows promise for tough head and neck cancers
Disease control CompletedThis phase 2 trial tested whether adding eftilagimod alpha to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that cannot be removed by surgery. The study included 171 participants whose tumors had certain marker…
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a common supplement ease cancer treatment pain?
Symptom relief CompletedThis early-phase study tested whether alpha lipoic acid, a dietary supplement, can reduce pain and side effects in people with head and neck cancer undergoing chemoradiation. Only 5 patients were enrolled to find a safe and tolerable dose. The goal was to see if it's worth studyi…
Matched conditions: HNSCC
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Cancer patients may not need lifelong immunotherapy, study suggests
Knowledge-focused CompletedThis study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…
Matched conditions: HNSCC
Phase: PHASE3 • Sponsor: Dan Zandberg • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC